sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Biosimilars Market (Follow-on-Biologics) by Types (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Peptide) and Application (Blood disorders, Oncology diseases, Growth hormone deficiencies) - Global Opportunity Analysis and Industry Forecast, 2014-2020

Biosimilars Market (Follow-on-Biologics) by Types (Human growth hormone, Erythropoietin, Monoclonal...

Home / Categories / Healthcare
Biosimilars Market (Follow-on-Biologics) by Types (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Peptide) and Application (Blood disorders, Oncology diseases, Growth hormone deficiencies) - Global Opportunity Analysis and Industry Forecast, 2014-2020
Biosimilars Market (Follow-on-Biologics) by Types...
Report Code
RO1/113/1018

Publish Date
25/Nov/2024

Pages
120
PRICE
$ 5540/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 6654/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 9280/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
TABLE 1 BIOSIMILARS MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2 BIOSIMILARS RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3 BIOSIMILARS DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 BIOSIMILARS GUIDELINES ADOPTED BY REGIONS
TABLE 5 COMPARISON OF BIOSIMILAR MEDICINE GUIDELINES BY GEOGRAPHY (2013)
TABLE 6 BIOSIMILARS DEVELOPMENT 2013 (LATIN AMERICA)
TABLE 7 OFF GOING PATENTS 2013-2016
TABLE 8 PREVALENCE OF TOP TWO CHRONIC DISEASES (2013)
TABLE 9 BIOSIMILAR DEVELOPMENT STATUS (2013)
TABLE 10 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2014-2020 ($MILLION)
TABLE 11 PATENTS STATUS FOR THE HUMAN GROWTH HORMONE (BIOLOGICS)
TABLE 12 PATENT EXPIRATION STATUS FOR HUMAN GROWTH HORMONE DURING 2014-2020 (BIOLOGICS)
TABLE 13 GLOBAL HGH BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)
TABLE 14 PATENTS APPROVED FOR INSULIN (BIOLOGICS)
TABLE 15 GLOBAL INSULIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)
TABLE 16 PATENTS APPROVED FOR INTERFERON (BIOLOGICS)
TABLE 17 PATENT EXPIRATION STATUS FOR INTERFERON DURING, 2014-2020 (BIOLOGICS)
TABLE 18 GLOBAL INTERFERON BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 19 PATENT EXPIRATION STATUS FOR G-CSF BIOSIMILARS DURING, 2014-2020 (BIOLOGICS)
TABLE 20 GLOBAL G-CSF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 21 PATENTS STATUS FOR ERYTHROPOIETIN (BIOLOGICS)
TABLE 22 PATENT EXPIRATION STATUS FOR ERYTHROPOIETIN DURING 2014-2020 (BIOLOGICS)
TABLE 23 GLOBAL ERYTHROPOIETIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 24 DRUG PATENT EXPIRATION FOR MONOCLONAL ANTIBODIES (BIOLOGICS)
TABLE 25 PATENT EXPIRATION STATUS FOR MONOCLONAL ANTIBODIES DURING, 2014-2020 (BIOLOGICS)
TABLE 26 GLOBAL MAB BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 27 GLOBAL PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014 -2020 ($MILLION)
TABLE 28 HIRUDIN BIOSIMILAR CANDIDATE STATUS
TABLE 29 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
TABLE 30 GLOBAL BLOOD DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 31 GLOBAL ONCOLOGY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 32 GLOBAL CHRONIC AND AUTOIMMUNE DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 33 GLOBAL GROWTH HORMONE DEFICIENCY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 34 GLOBAL OTHER DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 35 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 36 NORTH AMERICA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATION, 2014-2020 ($MILLION)
TABLE 37 BIOSIMILARS COMMERCIALLY AVAILABLE IN EUROPEAN UNION
TABLE 38 EUROPE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
TABLE 39 ASIA-PACIFIC BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
TABLE 40 LAMEA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
LIST OF FIGURE
FIG. 1 TOP FACTORS IMPACTING BIOSIMILARS MARKET (2014-2020)
FIG. 2 TOP WINING STRATEGIES FOR BIOSIMILARS MARKET DURING (2010-2015)
FIG. 3 TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENTS (2010-2015)
FIG. 4 TOP INVESTMENT POCKETS OF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET PRODUCTS, 2014-2020
FIG. 5 KEY ACHIEVEMENTS FOR BIOSIMILAR REGULATORS (2010)
FIG. 6 REGULATORY FRAMEWORK FOR BIOSIMILAR PRODUCTS IN CHINA
FIG. 7 PORTERS FIVE FORCE ANALYSIS OF BIOSIMILARS MARKET
FIG. 8 VALUE CHAIN ANALYSIS OF BIOSIMILARS MARKET
FIG. 9 IMPACT ANALYSIS OF STAKEHOLDERS INVOLVED IN PRIMARY ACTIVITIES (2014-2020)
FIG. 10 MARKET SHARE ANALYSIS OF BIOSIMILARS MARKET (2014)
FIG. 11 IMPACT ANALYSIS OF PRODUCT MARKET SEGMENTS (2014, 2020-2025)
FIG. 12 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
FIG. 13 IMPACT ANALYSIS OF APPLICATION MARKET SEGMENTS (2014-2020-2025)
FIG. 14 IMPACT OF REGULATION ON VARIOUS GEOGRAPHIES, 2012
FIG. 15 NET REVENUE GENERATION BY GEOGRAPHY (2013)
FIG. 16 NET REVENUE GENERATION BY BUSINESSES (2013)
FIG. 17 SWOT ANALYSIS OF NOVARTIS (SANDOZ)
FIG. 18 SWOT ANALYSIS OF SYNTHON PHARMACEUTICALS
FIG. 19 NET REVENUE GENERATION BY GEOGRAPHY (2013)
FIG. 20 NET REVENUE GENERATION BY BUSINESSES (2013)
FIG. 21 SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
FIG. 22 NET REVENUE GENERATION (2011-2013)
FIG. 23 SWOT ANALYSIS OF LG LIFE SCIENCES
FIG. 24 NET PROFIT DURING 2011-2013
FIG. 25 SWOT ANALYSIS OF CELLTRION
FIG. 26 REVENUE GENERATED BY BUSINESS UNITS (2013)
FIG. 27 SWOT ANALYSIS OF BIOCON
FIG. 28 NET SALES BY GEOGRAPHY (2013)
FIG. 29 NET SALES BY BUSINESS UNITS (2013)
FIG. 30 SWOT ANALYSIS OF HOSPIRA
FIG. 31 NET SALES BY GEOGRAPHY (2013)
FIG. 32 NET SALES BY BUSINESS UNITS (2013)
FIG. 33 SWOT ANALYSIS OF MERCK SERONO
FIG. 34 NET SALES BY GEOGRAPHY (2013)
FIG. 35 NET SALES BY BUSINESS UNITS (2013)
FIG. 36 SWOT ANALYSIS OF BIOGEN IDEC INC.
FIG. 37 SWOT ANALYSIS OF GENENTECH

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com